SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION GREEMENTIntercreditor and Subordination Greement • April 17th, 2017 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT (“Second Amendment”), dated as of April 6, 2017, by and among the holders of the Company’s Series E Preferred Stock (the “Series E Holders”) and the holders of the Company’s Series H Preferred Stock (“Series H Holders”), Amarantus Bioscience Holdings, Inc. (the “Company”), all of the subsidiaries of the Company (such subsidiaries, the “Subsidiaries”, the Company jointly and severally, together with their respective successors and assigns, collectively, the “Debtors”), GEMG LLC (“GEMG”), ANSON INVESTMENTS MASTER FUND LP (“Anson”), DOMINION CAPITAL, LLC, (“Dominion”) and DELAFIELD INVESTMENTS LIMITED (“Delafield”) the holders (collectively, the “April 2016 Holders”) of the Company’s 12% OID Senior Secured Convertible Promissory Notes, in the original aggregate principal amount of $9,125,000 pursuant to the Senior Loan Agreement, Delafield in its capacity as collateral agent (in such capacity, the “Collateral Agent”) and D
